Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy
Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy
Sponsor: National Cancer Institute (NCI)
A PHASE2/PHASE3 clinical study on Bladder Carcinoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 12 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 7 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — May 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2017 — Dec 2017 [monthly]
Recruiting PHASE2_PHASE3
Phase: NA → PHASE2_PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .